How Much Should We Still Worry About QTc Prolongation in Rifampicin-resistant Tuberculosis? ECG Findings from TB-PRACTECAL Clinical Trial

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2024 Jun 6

PMID 38842323

Authors

Ilaria Motta

Martina Cusinato

Andrew J Ludman

Nathalie Lachenal

Matthew Dodd

Moe Soe

Tleubergen Abdrasuliev

Ruzilya Usmanova

Ilhomjon Butabekov

Tigay Zinaida Nikolaevna

Irina Liverko

Nargiza Parpieva

Ronelle Moodliar

Varvara Solodovnikova

Emil Kazounis

Bern-Thomas Nyangwa

Katherine L Fielding

Catherine Berry

Affiliations

Soon will be listed here.

Abstract

Clinical Trials: This study is registered with ClinicalTrials.gov as NCT02589782.

Citing Articles

A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.

Lange C, Bothamley G, Gunther G, Guglielmetti L, Kontsevaya I, Kuksa L Pathog Immun. 2025; 10(2):1-45.

PMID: 40062355 PMC: 11888605. DOI: 10.20411/pai.v10i2.791.

Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital.

Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, Vittozzi P Antibiotics (Basel). 2025; 14(1.

PMID: 39858293 PMC: 11762953. DOI: 10.3390/antibiotics14010007.

Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?.

Pontali E, Raviglione M IJTLD Open. 2024; 1(11):486-489.

PMID: 39544882 PMC: 11558786. DOI: 10.5588/ijtldopen.24.0490.

References

Brust J, Gandhi N, Wasserman S, Maartens G, Omar S, Ismail N . Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study. Clin Infect Dis. 2021; 73(11):2083-2092. PMC: 8664482. DOI: 10.1093/cid/ciab335. View

Putra O, Yulistiani Y, Soedarsono S . Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis. Int J Mycobacteriol. 2022; 11(4):349-355. DOI: 10.4103/ijmy.ijmy_178_22. View

Nyangwa B, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z . A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022; 387(25):2331-2343. DOI: 10.1056/NEJMoa2117166. View

Hughes G, Bern H, Chiang C, Goodall R, Nunn A, Rusen I . QT prolongation in the STREAM Stage 1 Trial. Int J Tuberc Lung Dis. 2022; 26(4):334-340. PMC: 8982645. DOI: 10.5588/ijtld.21.0403. View

Rabkin S . Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics. Can J Psychiatry. 2015; 60(5):206-14. PMC: 4484689. DOI: 10.1177/070674371506000502. View

Li H, Salinger D, Everitt D, Li M, Del Parigi A, Mendel C . Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis. Antimicrob Agents Chemother. 2019; 63(10). PMC: 6761551. DOI: 10.1128/AAC.00445-19. View

Vandenberk B, Vandael E, Robyns T, Vandenberghe J, Garweg C, Foulon V . Which QT Correction Formulae to Use for QT Monitoring?. J Am Heart Assoc. 2016; 5(6). PMC: 4937268. DOI: 10.1161/JAHA.116.003264. View

Niemeijer M, van den Berg M, Eijgelsheim M, Rijnbeek P, Stricker B . Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update. Drug Saf. 2015; 38(10):855-67. PMC: 4579250. DOI: 10.1007/s40264-015-0316-6. View

Pym A, Diacon A, Tang S, Conradie F, Danilovits M, Chuchottaworn C . Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2015; 47(2):564-74. DOI: 10.1183/13993003.00724-2015. View

10.

Jayanthi R, Girijasivam S, Gaur A . Association of blood pressure and BMI to corrected QT interval in young adults. Can J Physiol Pharmacol. 2021; 99(9):894-899. DOI: 10.1139/cjpp-2020-0520. View

11.

Roden D . Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350(10):1013-22. DOI: 10.1056/NEJMra032426. View

12.

Hernan M, Hernandez-Diaz S, Werler M, Mitchell A . Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol. 2002; 155(2):176-84. DOI: 10.1093/aje/155.2.176. View

13.

Kusmiati T, Mertaniasih N, Putranto J, Suprapti B, Luthfah N, Soedarsono S . Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens. J Clin Tuberc Other Mycobact Dis. 2022; 28:100320. PMC: 9189108. DOI: 10.1016/j.jctube.2022.100320. View

14.

van Beek S, Tanneau L, Meintjes G, Wasserman S, Gandhi N, Campbell A . Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment. Open Forum Infect Dis. 2022; 9(8):ofac372. PMC: 9420883. DOI: 10.1093/ofid/ofac372. View

15.

Isralls S, Baisley K, Ngam E, Grant A, Millard J . QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study. Open Forum Infect Dis. 2021; 8(8):ofab413. PMC: 8403230. DOI: 10.1093/ofid/ofab413. View

16.

Diacon A, Pym A, Grobusch M, de los Rios J, Gotuzzo E, Vasilyeva I . Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014; 371(8):723-32. DOI: 10.1056/NEJMoa1313865. View

17.

Trinkley K, Page 2nd R, Lien H, Yamanouye K, Tisdale J . QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013; 29(12):1719-26. DOI: 10.1185/03007995.2013.840568. View

18.

Conradie F, Bagdasaryan T, Borisov S, Howell P, Mikiashvili L, Ngubane N . Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022; 387(9):810-823. PMC: 9490302. DOI: 10.1056/NEJMoa2119430. View

19.

Royston P, Ambler G, Sauerbrei W . The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999; 28(5):964-74. DOI: 10.1093/ije/28.5.964. View

20.

Kakkar A, Dahiya N . Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis (Edinb). 2014; 94(4):357-62. DOI: 10.1016/j.tube.2014.04.001. View